Listen on the go
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
CORRECT!
Next question
Faculty & Disclosures
Dr Yassir Javaid

Nene CCG, Northamptonshire, UK

Dr Javaid graduated from Cambridge University and completed his vocational training scheme in Northampton, UK. He has a specialist interest in cardiology and echocardiography and is the cardiovascular lead at the Nene Clinical Commissioning Group and primary care cardiovascular lead for the East Midlands Clinical Network. read more

He was named Pulse ‘GP of the Year’ in 2015 for his work in reducing stroke emergency admissions in the East Midlands. He is also a council member of the British Heart Valve Society, accredited member of the British Society of Echocardiography and on the editorial board for the British Journal of Cardiology. 

Dr Yassir Javaid discloses: Advisory board/panel fees from AstraZeneca, Bayer, Daiichi Sankyo and Novartis. Speaker’s bureau fees from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Eli Lilly, iRhythm, Medtronic, Menarini, MSD, Napp, Novartis, Novo Nordisk, Pfizer, Sanofi and Servier.
Prof. Tina Vilsbøll

Steno Diabetes Center Copenhagen and University of Copenhagen, Denmark

Prof. Tina Vilsbøll has been involved in diabetes research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark, which is now part of the Steno Diabetes Center Copenhagen. read more

Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, regulation of appetite and food intake, and the utilization of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years. Prof. Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research. In addition to her teaching and research posts, she is a member of numerous professional societies and committees, and referees for several international journals. 

She has contributed to more than 390 scientific publications (H-index 75), and edited or written numerous books and book chapters. She is a frequently invited speaker at international meetings.

Prof. Tina Vilsbøll discloses: Advisory board/panel fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Gilead, GSK, Eli Lilly, Novo Nordisk, Sanofi and Sun Pharmaceuticals. Consultant for Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Novo Nordisk, Sanofi and Sun Pharmaceuticals. Grants/research support from Boehringer Ingelheim and Novo Nordisk. Speaker’s bureau fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Novo Nordisk, Sanofi and Servier.
Prof. Georgios Tsivgoulis

National and Kapodistrian University of Athens, Greece

Prof. Georgios Tsivgoulis currently serves as professor of neurology and chairman in the Second Department of Neurology at the School of Medicine, National and Kapodistrian University of Athens. He is also the director of the Neurosonology Laboratory and of the Resident Training and Cerebrovascular Fellowship Program. In addition, he is a visiting professor of neurology and director of stroke research in the Department of Neurology at the University of Tennessee Health Science Center in Memphis, TN, USA. read more

Prof. Georgios Tsivgoulis’s research interests focus on acute reperfusion therapies in acute ischaemic stroke, applications of neurosonology in cerebrovascular diseases, secondary stroke prevention and clinical trial methodology. He has served as the national coordinator and International Steering Committee member in multiple phase II and III trials in acute stroke and in secondary stroke prevention. 

He is a fellow of the European Stroke Organization (ESO), European Academy of Neurology and American Academy of Neurology, and currently serves as general secretary of the Hellenic Society of Cerebrovascular Diseases, president of the Hellenic Neurological Society and vice president of ESO, where he is a member of the Guideline Board and serves on the Education Committee. Prof. Tsivgoulis has been the recipient of international awards, including the ESO Scientific Excellence Award 2021.

Prof. Tsivgoulis has authored more than 550 papers and 16 book chapters, and has been a reviewer for over 60 international medical journals. He is an associate editor of Therapeutic Advances in Neurological Disorders, a section editor of Stroke, and editor of Nevrologia. His research has received over 17,000 citations (Google Scholar) and his H-index is 66 (Google Scholar).

Prof. Georgios Tsivgoulis discloses: Advisory board/panel fees from Abbott, AbbVie, Actavis, Allergan, Bayer, Biogen, Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, Genesis Pharma, Ipsen, ITF Pharma, Medtronic, Merck, Novartis, Sanofi, Shionogi, Shire, Specifar, Teva and Takeda. Grants/research support from Abbott, AbbVie, Allergan, Amicus, Bayer, Boehringer Ingelheim, Genesis Pharma, Ipsen, Medtronic, Merck, Novalis, Novartis, Roche, Shire and Teva.
Ms Hyvelle Ferguson-Davis

Fort Lauderdale, FL, USA

Hyvelle Ferguson-Davis is a mother, wife, and stroke and heart attack survivor who continues to live a fulfilling life despite living with type 2 diabetes and heart-related challenges. read more

She is a graduate of Florida Atlantic University and is an ambassador for the American Heart Association and the American Diabetes Association, as well as an inspirational speaker and writer.

Ms Ferguson-Davis is the founder of Heart Sistas, an organization that aims to heighten awareness and deliver education about women’s health to a diverse group of underrepresented women.

Ms Hyvelle Ferguson-Davis discloses: Advisory board/panel fees from Boehringer Ingelheim.
touchNEUROLOGY touchNEUROLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Stroke

    EU STROKE PARTNER

    INTERNATIONAL STROKE PARTNER

    EUROPEAN PARTNER

    An Introduction to Stroke

    Most strokes (85%) are caused by acute ischaemia due to blockage of a cerebral artery, leading to loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral or subarachnoid haemorrhage. Treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytics and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. Increasingly, oral anticoagulants are preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia (e.g. transplantation of mesenchymal stem cells) are also emerging as potentially useful.

    Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Stroke Content

    Alzheimer's Disease and Dementia, Brain Trauma, COVID-19, Epilepsy, Headache Disorders, Neurodegenerative Diseases, Movement Disorders, Multiple Sclerosis, Neuroimmunology, Neurological Oncology, Neurometabolic Disease, Neuromuscular Diseases, Neuropathic Pain, Stroke, Neurosurgery, Paediatric Neurology, Parkinson's Disease, Psychiatric Disorders, Sleep Disorders, Central Nervous Disorders, Neuroradiology
    BrainGPT: Advancing neuroscientific research with AI

    In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.

    Brain Trauma, Stroke, Neurosurgery
    Challenges and motivations in neurocritical care: Insights from Dr Eric Lawson

    In this insightful Q&A, Dr Lawson shares the inspirations and motivations that led him to pursue a career in neurocritical care, the challenges he faces in this demanding specialty and his vision for the future of the field.

    Stroke
    Study uncovers growing stroke burden worldwide

    A study published in The Lancet Neurology reveals a troubling stagnation in the progress against stroke burden worldwide, with incidence rates failing to decline significantly since 2015. This analysis of the Global Burden of Disease (GBD) Study 2021 shows that the absolute numbers of strokes, related deaths and disability-adjusted life years (DALYs) have all risen considerably from 1990 to 2021, despite earlier global efforts aimed at reducing stroke mortality

    Stroke, Neurosurgery
    Watch Time: 47 mins
    touchTALKS
    Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies
    CE/CME ACCREDITED Prof. Dr. med. Jan Beyer-Westendorf Translations available:

    Watch an expert in thrombosis and haemostasis address reversal strategies in patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH).

    Learning objectives
    Learning Objectives
    • Recognize the risk of intracranial haemorrhage (ICH) in the era of direct oral anticoagulant (DOAC) therapy
    • Evaluate the latest clinical efficacy and safety data for approved reversal strategies in patients with DOAC-ICH
    • Outline the recommended guidelines on the management of DOAC-ICH
    Stroke
    Stroke Action Plan for Europe
    Aleš Tomek, Melinda B Roaldsen, Francesca Romana Pezzella

    touchREVIEWS in Neurology. 2024;20(2):6-8

    What is the Stroke Action Plan for Europe? Stroke is one of the most enormous burdens to healthcare services.1 Despite our combined efforts, it affects more than one million people annually in Europe. Although we have abundant knowledge regarding stroke prevention and treatment, there is still a significant gap between the theory and real-world stroke care, […]

    Stroke
    Elevation of Serum Oncostatin M Level in Acute Ischaemic Stroke: A Review
    Michael Christian, Youdong Wei

    touchREVIEWS in Neurology. 2024;20(1):33-36

    Introduction The term ‘stroke’ is used to describe an adverse clinical state involving interference of blood circulation to the brain due to obstruction or rupture of blood vessels.1 Stroke was previously categorized into a cardiovascular disorder until the release of the International Classification of Disease 11 (ICF-11) in 2018, when stroke was recognized as a neurological […]

    Paediatric Neurology, Stroke, Rare Diseases
    Watch Time: 39 mins
    touchPANEL DISCUSSION
    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
    CE/CME ACCREDITED Prof. Biree Andemariam, Prof. Modupe Idowu, Prof. Mark C Walters

    Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

    Learning objectives
    Learning Objectives
    • Summarize the various manifestations and multiple complications of SCD
    • Appraise the practical considerations for the multidisciplinary management of SCD complications
    • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
    Stroke, Brain Trauma, Neurosurgery
    Watch Time: 34 mins
    touchEXPERT OPINIONS
    Integrating the latest evidence surrounding reversal agents for direct oral anticoagulants for patients experiencing intracerebral haemorrhage into clinical practice
    CE/CME ACCREDITED Prof. Hanne Christensen, Prof. Thorsten Steiner, Dr Truman Milling Translations available:

    Watch three experts provide insights on the impact of ICH in patients receiving DOACs, DOAC-ICH reversal agents and optimizing treatment outcomes.

    Learning objectives
    Learning Objectives
    • Recognize the risk of ICH amongst different patient populations receiving DOACs based on clinical trial and real-world evidence
    • Appraise the latest clinical trial and real-world evidence on the efficacy and safety of oral anticoagulant reversal strategies in the acute management of DOAC-ICH
    • Assess the factors guiding selection and administration of reversal agents and supportive care in the acute management of DOAC-ICH
    Stroke
    Developed by Touch
    Update on the European Stroke Organisation Conference (ESOC) 2023: Peter Kelly
    Watch Time: 6 mins

    The European Stroke Organisation Conference (ESOC) 2023 will take place 24-26 May 2023 in Munich, Germany. The conference will include sessions, plenary lectures, and symposia, covering a wide range of topics related to stroke, including acute management, rehabilitation, imaging, epidemiology, and public health. Prof. Peter Kelly (President, European Stroke Organisation, Dublin, Ireland) joins touchNEUROLOGY to […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchNEUROLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup